8x8 Inc vs Vir Biotechnology Inc. Common Stock — how do they compare? 8x8 Inc trades at $2.02 (market cap $290.32M), while Vir Biotechnology Inc. Common Stock trades at $10.49 (market cap $1.76B). The key difference: Vir Biotechnology Inc. Common Stock is far larger — about 6.1× 8x8 Inc's market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| EGHT | VIR | |
|---|---|---|
Market Cap | $290.32M | $1.76B |
Volume | 1,226,387 | 2,764,948 |
Sector | Technology | Health |
52-Week High | $2.76 | $11.78 |
52-Week Low | $1.59 | $5.12 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $557.24M | $1.32B |
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.05, up 0.49% with a bullish technical signal despite bearish moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights cost-saving client wins and AI platform growth, while analyst consensus remains divided with a $19.77 price target representing significant upside potential from current levels.
EGHT presents a high-risk, high-reward opportunity with substantial upside to analyst targets but faces execution risks amid negative earnings. The stock's low price-to-sales ratio of 0.39 suggests undervaluation, though high debt levels and thin margins require careful monitoring. Positive momentum in AI adoption and client acquisitions could drive revaluation if profitability targets are met.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →